Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

OBJECTIVE: JAK inhibitors have shown efficacy in rheumatoid arthritis (RA). We undertook this study to test our hypothesis that selective inhibition of JAK‐1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors. METHODS: In two 4‐week exploratory, doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanhoutte, Frédéric, Mazur, Minodora, Voloshyn, Oleksandr, Stanislavchuk, Mykola, Van der Aa, Annegret, Namour, Florence, Galien, René, Meuleners, Luc, van 't Klooster, Gerben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656813/
https://www.ncbi.nlm.nih.gov/pubmed/28622463
http://dx.doi.org/10.1002/art.40186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656813/
https://www.ncbi.nlm.nih.gov/pubmed/28622463
http://dx.doi.org/10.1002/art.40186

Ejemplares similares